Publication: Beta-blockers and COPD: the show must go on.
No Thumbnail Available
Identifiers
Date
2016-08-31
Authors
Lopez-Campos, Jose Luis
Marquez-Martin, Eduardo
Casanova, Ciro
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
European Respiratory Society
Abstract
Identification of comorbidities is now recognised as one of the pillars for a comprehensive clinical evaluation in chronic obstructive pulmonary disease (COPD) [1]. Specifically, the burden of coexisting cardiovascular disease in COPD has gained significant attention, with specific algorithms being developed for its clinical detection [2]. The relationship between the heart and COPD is of clinical relevance not only for the well-documented relationship between the two organs [3], but also for the potential mutual influence of treatments. The interactions between oral beta-blockers and inhaled β-adrenergic drugs pose significant challenges for clinicians involved in the management of patients with chronic cardiorespiratory conditions. In particular, the use of beta-blockers in COPD remains the subject of ongoing controversy
Description
MeSH Terms
Adrenergic beta-Antagonists
Humans
Pulmonary Disease, Chronic Obstructive
Humans
Pulmonary Disease, Chronic Obstructive
DeCS Terms
Enfermedad Pulmonar Obstructiva Crónica
Pacientes
Corazón
Diagnóstico
Enfermedades cardiovasculares
Relevancia clínica
Adrenérgicos
Atención
Pacientes
Corazón
Diagnóstico
Enfermedades cardiovasculares
Relevancia clínica
Adrenérgicos
Atención
CIE Terms
Keywords
Adrenergic Agents, Clinical Relevance, Cardiovascular Diseases, Heart
Citation
Lopez-Campos JL, Márquez-Martín E, Casanova C. Beta-blockers and COPD: the show must go on. Eur Respir J. 2016 Sep;48(3):600-3.